OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Total Current Liabilities
All obligations due within one year.
OptimizeRx CorporationNASDAQ: OPRX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 43.0% from a year ago
Total current liabilities stood at $10.46M at the end of Q1 FY2026, down 43.0% from a year earlier and down 50.8% from the prior quarter. Over 3 fiscal years it compounded at +36.3% a year.
Context
- Total current liabilities amounted to 6.3% of total assets at the end of Q1 FY2026, down 4.7 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -43.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 21.26M USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- +22.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.26M | +14.0% |
| FY2024 | 2024-12-31 | 18.65M | +4.3% |
| FY2023 | 2023-12-31 | 17.88M | +113.0% |
| FY2022 | 2022-12-31 | 8.4M | -10.4% |
| FY2021 | 2021-12-31 | 9.37M | — |
Total Current Liabilities vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -43.0% is the lowest of 10, against a peer median of +19.0%.
- Total current liabilities amounts to 6.3% of total assets for OPRX, versus a peer median of 22.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $251.7M USD | +44653.7% | +770.1% | 40.5% | |
| Mar 2026 | $140.4M USD | -10.0% | +3.7% | 27.3% | |
| Mar 2026 | $61.5M USD | +19.0% | +9.2% | 15.1% | |
| Mar 2026 | $46.6M USD | +61.0% | +23.5% | 29.7% | |
| Mar 2026 | $43.45M USD | +6.6% | -2.8% | 22.4% | |
| Mar 2026 | $38.47M USD | +1.8% | +3.1% | 28.6% | |
| Mar 2026 | $27.38M USD | +20.4% | +15.1% | 9.0% | |
| Feb 2026 | $12.34M USD | +15.4% | -4.6% | 8.4% | |
| Mar 2026 | $10.46M USD | -43.0% | +36.3% | 6.3% | |
| Mar 2026 | CA$3.83M CAD | +500.3% | +16.6% | 1.2% | |
| Peer median (excluding OPRX) | — | +19.0% | +9.2% | 22.4% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84.68M | 18.21M | 13.85M | 13.38M | 23.37M |
| Short-term Investments | 0 | 55.93M | 0 | 0 | 0 |
| Net Receivables | 24.8M | 22.16M | 37.29M | 38.21M | 37.75M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 608.15K | 473.65K | 404.47K | 387K | 752K |
| Total Current Assets | 115.11M | 98.58M | 54.33M | 53.97M | 64.72M |
| Property, Plant & Equipment (Net) | 472.64K | 372.77K | 722.3K | 516K | 510K |
| Goodwill | 14.74M | 22.67M | 78.36M | 70.87M | 70.87M |
| Intangible Assets | 10.65M | 13.02M | 49.4M | 45.52M | 40.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.86K | 5.05K | 568.05K | 296K | 28K |
| Total Non-current Assets | 25.87M | 36.07M | 129.04M | 117.2M | 112.2M |
| Total Assets | 140.99M | 134.65M | 183.37M | 171.17M | 176.92M |
| Account Payables | 606.81K | 1.55M | 2.23M | 2.16M | 1.64M |
| Short-term Debt | 0 | 0 | 2M | 2M | 4.26M |
| Tax Payables | 0 | 0 | 49K | 318K | 0 |
| Deferred Revenue | 1.39M | 164.31K | 171.84K | 473K | 503K |
| Other Current Liabilities | 0 | 0 | 5.55M | 0 | 3.09M |
| Total Current Liabilities | 9.37M | 8.4M | 17.88M | 18.65M | 21.26M |
| Long-term Debt | 0 | 0 | 34.23M | 30.82M | 21.42M |
| Deferred Tax Liabilities | 0 | 0 | 4.34M | 4.49M | 5.71M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 236.73K | 144.53K | 38.94M | 35.52M | 27.36M |
| Total Liabilities | 9.61M | 8.54M | 56.82M | 54.17M | 48.62M |
| Common Stock | 17.86K | 18.29K | 19.9K | 20K | 20K |
| Retained Earnings | (35.25M) | (46.69M) | (64.26M) | (84.37M) | (79.24M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 131.38M | 126.11M | 126.55M | 117M | 128.29M |
| Total Debt | 327.71K | 234.43K | 36.82M | 33.19M | 26.1M |
| Net Debt | (84.35M) | (17.97M) | 22.97M | 19.81M | 2.74M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.